Comparative Pharmacology
Head-to-head clinical analysis: ANJESO versus EC NAPROSYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANJESO versus EC NAPROSYN.
ANJESO vs EC-NAPROSYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing inflammation and pain.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
120 mg administered intravenously over 15 minutes, followed by 30 mg intravenously over 15 minutes, with the second dose given 12 to 24 hours after the first dose.
500-1000 mg orally twice daily; maximum 1500 mg/day.
None Documented
None Documented
Terminal elimination half-life is 1.5-2.5 hours in healthy adults. In elderly or renally impaired patients, half-life may extend to up to 6 hours.
Terminal elimination half-life 12-17 hours (mean 14 hours); prolonged in elderly and renal impairment
Approximately 70% renal (30% unchanged, 40% as glucuronide conjugate), 30% fecal/biliary.
Renal (95%) as unchanged drug (10%) and conjugated metabolites (60%) and other metabolites (25%); biliary/fecal (5%)
Category C
Category C
NSAID
NSAID